Who we are
MucoLife Therapeutics was born from a shared passion to revolutionize the treatment of mucus obstruction in chronic pulmonary diseases that affect millions across the globe. Founded by researcher and visionary entrepreneurs from the Mucin Biology Groups at University of Gothenburg, we leverage 40 years of groundbreaking research in mucin biology to bring benefit for the patients.
We are developing a pipeline of innovative medications targeting obstructive mucus accumulation in COPD and other chronic pulmonary diseases.
Together with our investors, we are dedicated to transform healthcare and improving the lives of millions.
Meet the Team
-
Thaher Pelaseyed, PhD
Co-founder/CEO
tpelaseyed@mucolife.com
Linkedin proifle -
Gunnar C. Hansson, MD PhD
Co-founder/CSO
ghansson@mucolife.com
Linkedin profile -
Anders Waas
Board Director
awaas@mucolife.com
Linkedin profile -
Malin Johansson, PhD
Board member
-
Jesper Magnusson, MD PhD
Board member
-
Sergio Trillo-Muyo, PhD
CTO
-
Jesper Dahlberg
Board member
Our Advisors
-
Kicki Johansson, PhD
20 years as an effective project leader of drug development projects (preclinic- end of phase II) with successful governance, regulatory and other stakeholder buy-in. Strong science background with disease area experience of thrombosis, dyslipidaemia, atherosclerosis, diabetes, obesity, GI, oncology, and asthma.
